The Early Experience With Vedolizumab in the United States

BACKGROUND: Post-marketing studies of new inflammatory bowel disease (IBD) therapies are needed to establish clinical effectiveness and safety in clinical practice. We aimed to describe the U.S. experience with vedolizumab in a commercially insured population. METHODS: We conducted a retrospective c...

Descripción completa

Detalles Bibliográficos
Autores principales: Kochar, Bharati, Jiang, Yue, Winn, Aaron, Barnes, Edward L, Martin, Christopher F, Long, Millie D, Kappelman, Michael D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Observations And Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6798787/
https://www.ncbi.nlm.nih.gov/pubmed/31667469
http://dx.doi.org/10.1093/crocol/otz027

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6798787/
https://www.ncbi.nlm.nih.gov/pubmed/31667469
http://dx.doi.org/10.1093/crocol/otz027

Ejemplares similares